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Abstract
Background: Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy in patients
with ST-elevation myocardial infarction (STEMI), but its benefit over prehospital fibrinolysis (FL) is not clear.
Methods: We performed a systematic review and meta-analysis of randomized controlled trials in which outcomes
of patients with STEMI managed with FL early in the prehospital setting versus PPCI were compared.
Results: Compared with PPCI, FL was consistently associated with similar rates of short-term (30–90 days) death
(relative risk [RR] 0.94, 95 % CI 0.67–1.31) and cardiovascular death (RR 0.95, 95 % CI 0.64–1.4), a decreased risk of
cardiogenic shock (RR 0.67, 95 % CI 0.48–0.95), and an increased risk of any stroke (RR 3.57, 95 % CI 1.39–9.17) and
hemorrhagic stroke (RR 4.37, 95 % CI 1.25–15.26). FL was also associated with similar rates of 1-year mortality (RR 1.
01, 95 % CI 0.75–1.34) and major bleeding (RR 1.31, 95 % CI 0.96–1.78) in comparison with PPCI, but with a notable
level (I2 index 30.5 % and 59.8 %) of heterogeneity among studies.
Conclusions: Our study suggests that, compared with PPCI, FL performed in the early prehospital setting is
associated with similar mortality rates, lower rates of cardiogenic shock, and higher rates of stroke in patients
with STEMI. Although the number of studies comparing the two strategies is relatively low, our results support
prehospital FL and transfer to hub percutaneous coronary intervention (PCI) centers as a valid alternative to PPCI,
allowing potential limitation of resources allocated to developing proximity 24/7 PCI facilities.
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Background
Primary percutaneous coronary intervention (PPCI) is
considered the preferred reperfusion strategy in patients
with ST-elevation myocardial infarction (STEMI), pro-
vided it can be performed expeditiously by an experienced
team [1], based on studies comparing PPCI with in-
hospital fibrinolysis (FL) [2]. International guidelines also
underscore the objective of a total ischemic time <2 h in
STEMI, which may not always be achievable if a PPCI
strategy is chosen. Prehospital FL and direct transfer to a
percutaneous coronary intervention (PCI)-capable center,
which should be considered only when the estimated total
ischemic time is >2 h after first medical contact in STEMI
patients, is recommended over transfer for in-hospital FL
when possible [3, 4].
Importantly, the relative benefit of PPCI over fibrino-
lytic therapy is time-dependent [5]. The benefit of PPCI
over prehospital FL is not clear among patients managed
early in the prehospital setting. The Comparison of pri-
mary Angioplasty and Pre-hospital fibrinolysis In acute
Myocardial infarction (CAPTIM) trial [6] was the first
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large-scale trial comparing the two strategies. It showed
that PPCI was not associated with lower mortality rates
than prehospital FL. That study was terminated before
reaching its target sample size, however. Researchers in
the more recent Strategic Reperfusion Early after Myo-
cardial Infarction (STREAM) trial [7] also reported
similar rates of mortality between prehospital FL or
PPCI. Both studies were undersized to assess a differ-
ence in mortality. In a real-life French nationwide
registry of STEMI, prehospital FL was associated with
reduced mortality in comparison with PPCI [8]. Hence,
the benefit of allocating resources to developing proxim-
ity centers with 24/7 PCI facilities over prehospital FL
and transfer to hub PCI centers may be questionable.
The principal objective of the present systematic re-
view and meta-analysis of randomized controlled trials




We conducted a systematic literature review by formal
searches of the electronic databases MEDLINE (source
PubMed) and the Cochrane Controlled Clinical Trials
Register Database through January 2015. Relevant random-
ized controlled trials were identified by a combination of
medical subject headings including the following terms:
“myocardial infarction”, “acute myocardial infarction”,
“STEMI”, “fibrinolytic therapy”, “fibrinolysis”, “thromboly-
sis”, “thrombolytic therapy”, “percutaneous coronary
intervention”, “primary PCI”, and “primary angioplasty.”
References from reviews and selected articles were also
reviewed for potential relevant citations. Studies were se-
lected by two independent reviewers (VR and PA).
We restricted our analysis to the trials that met all of
the following inclusion criteria: (1) randomized con-
trolled comparison between prehospital FL and PPCI,
(2) in patients with STEMI managed in the prehospital
setting early after symptom onset (<6 h), and (3) avail-
able data on mortality.
The primary outcome assessed in our analysis was
mortality as reported in the principal publications.
Other outcomes were recurrent myocardial infarction
(MI), cardiogenic shock, stroke (hemorrhagic and is-
chemic), and the major bleeding as defined in each
study. The meta-analysis of the primary composite
endpoint of the studies was performed but should be
considered only as exploratory because of the inclu-
sion of different events in different studies and the
subsequent risk of unpredictable sources of bias. Out-
comes were based on the longest follow-up available
for each study. We excluded studies that associated
FL with glycoprotein IIb/IIIa inhibitors and studies
with no clinical endpoint.
Statistical analysis
The total numbers of patients experiencing or not the
outcomes of interest in each arm extracted directly from
the publications were used for the analyses. Results are
presented as relative risks (RRs) with 95 % CIs. Out-
comes from individual studies were combined using
Mantel-Haenszel fixed effect and random-effects models.
Heterogeneity across studies was evaluated by the
Cochran’s Q statistic with a p value set at 0.1. The I2
statistic was also taken into account, regardless of the p
value. An I2 ≥ 50 % was prespecified as the threshold
considered too high to provide consistent analysis.
The random-effects model was considered for the pri-
mary analysis. A fixed effect model is also reported in
figures, considered as a sensitivity analysis only. We also
conducted a sensitivity analysis based on a study-by-
study exclusion process. Tests were two-tailed, and a p
value <0.05 was considered statistically significant. R
software version 3.0.0 (2013-04-03) for Mac OS (R
Foundation for Statistical Computing, Vienna, Austria)
with the Meta package was used for the statistical
analysis.
Results
Ultimately, three trials [6, 7, 9], comprising two long-
term follow-up studies of the latter [10, 11] and a post
hoc analysis of one trial [12], were selected for the meta-
analysis. The review process is depicted in Fig. 1. The
endpoints were collected at 30 days in the STREAM and
CAPTIM studies and at 90 days in the Assessment of
the Safety and Efficacy of a New Treatment Strategy
with Percutaneous Coronary Intervention (ASSENT-4
PCI) study. The major characteristics of the patients of
each study and the rates of the clinical endpoints are
detailed in Table 1.
The meta-analysis showed consistently that the rates
of short-term (30/90 days) death (RR 0.94, 95 % CI
0.67–1.31) (Fig. 2a) and cardiovascular death (RR
0.95, 95 % CI 0.64–1.4) (Fig. 2b) were similar between
prehospital FL and PPCI. Similar results were also
found for 1-year death (RR 1.01, 95 % CI 0.75–1.34)
(Fig. 2c) and MI (RR 1.37, 95 % CI 0.84–2.21)
(Fig. 2d) between the two strategies, but with nonsig-
nificant but notable heterogeneity (I2 index 30.5 %
and 34.6 %).
Consistently, compared with PPCI, the risk of cardio-
genic shock was lower (RR 0.67, 95 % CI 0.48–0.95)
(Fig. 2e), but the risks of stroke (RR 3.57, 95 % CI 1.39–
9.17) (Fig. 2f ) and hemorrhagic stroke (RR 4.37, 95 % CI
1.25–15.26) (Fig. 2 g) were higher, in association with
prehospital FL, whereas the risk of ischemic stroke (RR
2.44, 95 % CI 0.71–8.47) (Fig. 2 h) did not significantly
differ between the two strategies. Finally, the risk of
major bleeding (RR 1.31, 95 % CI 0.96–1.78) (Fig. 2i)
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was similar between the two strategies, but with a high
level of heterogeneity between the studies (I2 = 59.8 %).
Although the meta-analysis of the composite primary
endpoints showed similar results between FL and PPCI
(RR 0.99, 95 % CI 0.82–1.2), it should be considered only
as exploratory because different endpoints composed the
primary outcome of different studies. The sensitivity
analyses by random-effects analysis (Fig. 2) and by ex-
cluding study by study (Additional file 1: Table S1) did
not show any major change in the results of the princi-
pal analysis.
Discussion
Our meta-analysis suggests that prehospital FL is associ-
ated with similar early and late mortality rates compared
with PPCI in patients with STEMI managed early after
symptom onset in the prehospital setting. Prehospital FL
is also associated with a decreased risk of cardiogenic
shock. However, it was consistently associated with an
increased risk of stroke and hemorrhagic stroke.
In STEMI patients presenting in the first hours after
symptom onset, PPCI is the recommended default
reperfusion strategy if performed according to the
recommended time limits [1]. Because most of these pa-
tients present to non-PPCI-capable hospitals, this reper-
fusion strategy may be a major challenge in many
regions of the world [13]. Hence, recent trials have
shown that prehospital FL appears to be a valuable alter-
native [6, 7, 9]. Our meta-analysis confirms that mortal-
ity rates and, less consistently, ischemic composite
outcomes are similar between the two reperfusion strat-
egies. This is concordant with real-life registries report-
ing comparable in-hospital [14] and even higher 1- and
5-year survival rates [8, 15] associated with prehospital
FL compared with PPCI in similar populations. A major
advantage of prehospital FL is the time gained from
symptom onset to reperfusion (i.e., from symptom onset
to start of reperfusion treatment with tenecteplase or
alteplase in the FL group and first balloon inflation in
the PPCI group), ranging from 60 to 78 minutes in the
studies included in our analysis [6, 7, 9]. Such times are
reported in countries where the density of centers with
PPCI facilities is relatively high. Hence, it may be specu-
lated that in many other regions, such times are even
longer. Indeed, the time from symptom onset to reperfu-
sion is of critical importance for myocardial salvage [16].
2029 studies identified through 
electronic database search
1937studies excluded by non-relevant title and/or abstract
92 abstracts screened
10 full-length articles evaluated 
for inclusion
82 abstracts excluded
- meta analysis: 24
- retrospective studies: 7
- GPI associated with FL: 7
- in-hospital fibrinolysis: 36
- non-randomized studies: 7
- no clinical endpoint: 1
4 studies excluded
- study in Russian =1
- no available data for the prehospital group: 2
- GPI associated with FL: 1
6 studies selected for the 
analysis
Fig. 1 Flow diagram of meta-analysis trial selection. GPI Glycoprotein IIb/IIIa inhibitors, FL Fibrinolysis
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The use of a single-bolus fibrinolytic therapy as de-
scribed in the STREAM and ASSENT-4 PCI trials [7,
9], but not in the CAPTIM trial [6], may be prefera-
ble because of its quick and easy administration. The
use of continuous intravenous infusion of alteplase
may also explain the relatively shorter difference of
time from symptom onset to reperfusion therapy be-
tween the PPCI and FL groups in the CAPTIM trial
[6] than in other trials.
Prehospital FL is recommended [1, 3] in association
with early routine angiography, and PCI if needed. In
the studies included in our analysis, patients were
systematically transferred to PCI-capable centers and
had high rates of PCI (70.4 %, 80.4 %, and 86.7 %,
respectively, in the FL groups of the CAPTIM,
STREAM, and ASSENT-4 PCI trials). The Which
Early ST-elevation myocardial infarction Therapy
(WEST) study [17] researchers previously showed that
a strategy of early FL (only 18 % prehospital) coupled
with routine early invasive management results in
similar rates of death and recurrent MI compared
with PPCI. Unlike these favorable results, the large
Swedish registry [18] reported lower mortality rates in
association with PPCI than both in-hospital and pre-
hospital FL. Such discordance is probably explained
by the low rates of PCI in the prehospital FL group
Table 1 Demographic characteristics of the patients and clinical endpoints of selected studies
STREAM CAPTIM ASSENT-4 PCI
Prehospital FL
(n = 944)
PPCI (n = 948) Prehospital FL
(n = 419)
PPCI (n = 421) Prehospital FL
(n = 163)
PPCI (n = 171)
Demographics
Age, years 59.7 ± 12.4a 59.6 ± 12.5a 58 (49–69)b 58 (50–68)b 60 (51–69)b
Age ≥75 years 134 (14.2 %) 121(12.8 %) 42 (10.0 %) 40 (9.5 %) n/a n/a
Female sex 194 (20.6 %) 208 (21.9 %) 74 (17.5 %) 78 (18.5 %) 19.5 %
Diabetes 113/934 (12.1 %) 123/939 (13.1 %) 46 (11.1 %) 57 (13.5 %) 13.2 %
Hypertension 434/930 (46.7 %) 414/932 (44.4 %) 141 (33.9 %) 146 (34.8 %) 43.4 %
Dyslipidemia 212 (51.1 %) 215 (51.4 %) 35.9 %
Previous PCI 60/942 (6.4 %) 83/944 (8.8 %) 22 (5.3 %) 18 (4.3 %) 9.4 %
Previous CABG 2/944 (0.2 %) 3/946 (0.3 %) 0 5 (1.2 %) 1.2 %
Previous MI 81/940 (8.6 %) 98/947 (10.3 %) 34 (8.2 %) 28 (6.7 %) 11.5 %
Heart rate 74.9 ± 18.4 75.5 ± 18.1 76 (64–84) 75 (66–88) n/a n/a
Systolic blood pressure, mmHg 135.0 ± 22.7 135.9 ± 14.9 125 (110–140) 128 (111–140) n/a n/a
Anterior MI 453/942 (48.1 %) 431/946 (45.6 %) 166 (40.2 %) 178 (42.7 %) 45.8 %
Median time delay (IQR), minutes
Symptom onset to randomization,
minutes
91 (68–132) 92 (65–132) 107 (76–158) 108 (76–162) 105 (75–172) 105 (70–160)




100 (75–143) 178 (135–230) 130 (95–180) 190 (149–255) 125 (90–185) 203 (154–258)
PCI 736/915 (80.4 %) 838/933 (89.9 %) 295 (70.4 %) 364 (86.5 %) n/a n/a
Endpoints
Primary composite endpointc 116/939 (12.4 %) 135/943 (14.3 %) 34 (8.2 %) 26 (6.2 %) 31/161 (19.3 %) 23/165 (13.9 %)
Death 43/939 (4.6 %) 42/946 (4.4 %) 16 (3.8 %) 20 (4.8 %) 5/163 (3.1 %) 7/171 (4.1 %)
Stroke 15/939 (1.6 %) 5/946 (0.5 %) 4 (1.0 %) 0 n/a n/a
Reinfarction 23/938 (2.5 %) 21/944 (2.2 %) 15 (3.7 %) 7 (1.7 %) n/a n/a
Severe hemorrhage 70/939 (7.5 %) 47/946 (5 %) 2 (0.5 %) 8 (2.0 %) 13/163 (8.0 %) 11/171 (6.4 %)
Abbreviations: CABG Coronary artery bypass graft, MI Myocardial infarction, n/a Not available, PCI Percutaneous coronary intervention, PPCI Primary percutaneous
coronary intervention, ASSENT-4 PCI Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention study, CAPTIM




cThe primary composite endpoint was a composite of “death, shock, congestive heart failure or reinfarction at 30 days” for STREAM; “death, non-fatal reinfarction,
and non-fatal disabling stroke in 30 days” for CAPTIM; and “mortality, shock, or congestive heart failure within 90 days” for ASSENT-4 PCI
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(47.3 % of PCI or coronary artery bypass graft
[CABG] within 14 days) in this registry. The optimal
delay between successful FL and PCI is also a critical
issue. Compared with PPCI, prehospital tenecteplase-
facilitated PCI was associated with increased rates of
reinfarction and trends toward higher rates of mortal-
ity [9] and increased infarct size [19]. Such results are
explained by the paradoxical FL-induced platelet hy-
perreactivity and thrombin-induced platelet activation
within the early hours after FL [20]. Hence, the time
window of 3–24 h after successful FL is recom-
mended [1] and explains the excellent results of the
pharmacoinvasive strategy, as demonstrated in our
meta-analysis.
Trends toward lower rates of cardiogenic shock
occurrence with prehospital FL were noted in the
CAPTIM [6] and STREAM [7] trials as well as in the
WEST study [17]. Our meta-analysis shows a consist-
ent and significant reduction of rates of cardiogenic
shock complicating STEMI in association with prehos-
pital FL compared with PPCI. This is also consistent
with the fact that the most frequent cause of death
was cardiogenic shock in the trials [6, 9]. In the CAP-
TIM trial [6], all shocks that occurred during the
transport to the hospital were observed in the PPCI
group, suggesting that the 1-h additional delay in the
PPCI compared with prehospital FL may be respon-
sible for the higher cardiogenic shock rates.
However, our meta-analysis highlights the consistent
relative increase of the risks of stroke and
hemorrhagic stroke in association with prehospital FL
compared with PPCI. This finding may be tempered
by the low absolute rates of stroke in each study, how-
ever, potentially explained by the limited proportion of
elderly patients included. The increased risk of intra-
cranial bleeding in patients ≥75 years old in the
STREAM study [7] led to a dose reduction of tenecte-
plase in such patients. After the subsequent protocol
amendment, no cases of intracranial hemorrhage were
reported, and rates of mortality significantly dropped
in the FL arm [11]. Moreover, rates of major bleeding
did not significantly differ between the two strategies
in our analysis.
The time from symptom onset to first medical contact
as well as patient characteristics should be taken into ac-
count before selecting the reperfusion strategy [3]. In
the studies selected in our analysis, patients were in-
cluded if they presented within 3–6 h of symptom onset.
However, the benefit of prehospital FL may be even
more important in the first 2 h after symptom onset, as
it has previously been reported to be associated with an
improved 1-year survival compared with PPCI (2.8 %
versus 6.9 %, respectively; p = 0.021) and low rates of
intracranial hemorrhage (0.3 %) [21]. The patient’s risk
profile, stratified by age and infarct location (anterior
versus other), is also of importance in selecting the re-
perfusion strategy. In a large North American registry
including 192,509 patients [5], the mean PCI-related
time delay compared with FL, where mortality rates of
the two reperfusion strategies were comparable, was
calculated as 114 minutes in general. This delay was re-
duced to only 40 minutes in patients <65 years old pre-
senting with an anterior MI within 2 h of symptom
onset. In such patients with an extensive area of myocar-
dium at risk, low risk of intracranial hemorrhage, and
high chance of successful FL [22], a rapid and efficient
restoration of flow with prehospital FL may improve
myocardial salvage and outcome.
Fig. 2 Forest plots of CAPTIM, STREAM and ASSENT-4 PCI studies comparing the effect of prehospital fibrinolysis with primary percutaneous
coronary intervention on death (a), cardiovascular death (b), 1-year death (c), myocardial infarction (d), cardiogenic shock (e), stroke (f),
hemorrhagic stroke (g), ischemic stroke (h), and major bleeding (i). ASSENT-4 PCI Assessment of the Safety and Efficacy of a New Treatment
Strategy with Percutaneous Coronary Intervention study, CAPTIM Comparison of primary Angioplasty and Pre-hospital fibrinolysis In acute Myocardial
infarction trial, PCI Percutaneous coronary intervention, RR Relative risk, STREAM Strategic Reperfusion Early after Myocardial Infarction trial
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Study limitations
Our meta-analysis was not performed on individual pa-
tients’ data. Only few randomized trials, all included in
the present analysis, have compared prehospital FL with
PPCI. Aggregate data can be misleading in cases of few
available studies, especially for the exploration of differ-
ences across subgroups. The included studies have a cer-
tain degree of clinical heterogeneity, which is mirrored
by the statistical inconsistency found across some of the
outcomes (1-year mortality, MI, major bleeding). We ac-
knowledge this limitation of our study; however, the re-
sults are highly consistent for some major endpoints
(30-/90-day and cardiovascular mortality, shock, stroke,
hemorrhagic stroke), and the sensitivity analyses support
the robustness of our results.
Owing to the low number of studies, which is a limi-
tation but also a justification of the meta-analysis, con-
fidence intervals for events with low occurrence rates
(e.g., hemorrhagic stroke) are relatively large. Our con-
clusions do not apply to patients excluded from the
studies, particularly those with symptom onset to first
medical contact time >6 h, cardiogenic shock, a
previous CABG, or any contraindication to FL. Finally,
half-dose fibrinolytic therapy in patients >75 years old,
associated with a reduction of stroke rates in the
STREAM trial, was not applied in other studies.
Whether such dose adaptation may further improve the
results of fibrinolytic therapy needs to be tested by ad-
equate studies.
Conclusions
Our analysis suggests that prehospital FL is associated
with similar early and late mortality rates compared with
PPCI in patients with STEMI managed early after symp-
tom onset in the prehospital setting. Prehospital FL was
associated with a decreased risk of cardiogenic shock
but an increased risk of stroke. Prehospital FL appears
to be a valuable alternative to PPCI. Pharmacoinvasive
strategies including prehospital FL and transfer to hub
PCI centers may allow reduction of the cost allocated to
developing proximity centers with 24/7 PCI facilities
while providing similarly efficient reperfusion therapy.
Additional file
Additional file 1: Table S1. Sensitivity analysis (by excluding study
by study). (DOCX 14 kb)
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